A phase 1/2 trial of MHB039A in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.
A Study of MHB039A for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06345482 by Minghui Pharmaceutical (Hangzhou) Ltd, with 196 participants enrolled, started 2024-04-16 and due to reach its primary completion in 2028-04-01. Interventions recorded: MHB039A.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.